SAN FRANCISCO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) and a leading AI‑powered physician‑enablement platform, today announced that Blaine Lindsey, Vice President of Enterprise Growth and Partnerships and Shannon Jacobs, President of Market Operations for the Gulf Region have joined Counterpart Health. These two strategic leadership appointments are integral to nurturing new partnerships and ensuring operational support for successful adoption of Counterpart Assistant (CA).
These appointments come during a time when many physicians lack the technology infrastructure and operational support to successfully implement value-based care, especially in underserved areas where clinicians may have limited resources. CA addresses this gap by surfacing AI-powered insights into existing clinician workflows, enabling them to identify high-risk patients, manage chronic conditions earlier, and support value-based care at scale.
"Counterpart Assistant was built to serve the full spectrum of physician practices," said Conrad Wai, CEO of Counterpart Health. "Whether we're partnering with large health systems, national plans, regional payviders, or independent practices in rural communities, we’ve identified that the need is the same: actionable intelligence that improves care without overwhelming providers. Blaine and Shannon bring the expertise to scale our impact while ensuring we deliver meaningful results.”
Driving National Enterprise Partnerships
As Vice President of Enterprise Growth and Partnerships, Blaine Lindsey will be instrumental in bringing Counterpart Assistant to more risk-bearing organizations, and ultimately, more clinicians and patients. Lindsey is a highly accomplished healthcare leader and nationally recognized value-based care expert whose experience includes leading national provider and enterprise partnerships at Aledade and Honest Health as well as driving expansion as Chief Growth Officer at AnsibleHealth. Lindsey brings a proven track record of building innovative, high performance partnerships that deliver both clinical and financial value.
“Counterpart’s technology has proven itself in real-world deployments and consistently outperforms in actual practice settings,” said Blaine Lindsey. “The healthcare ecosystem is taking notice of Counterpart Assistant with new partners requesting access, and inbound demand is building quickly. My priority is to convert that momentum into strategic partnerships that deliver reliable, measurable results for clinicians while scaling adoption within existing workflows.”
Scaling Operations in the Gulf Region's Diverse Markets
Shannon Jacobs joins as President of Market Operations for the Gulf Region, where he'll lead the expansion and performance optimization of Counterpart’s growing physician network. Jacobs most recently served as President of the Gulf Region at Main Street Health, the nation's largest value-based care provider in rural communities. He brings deep operational expertise in launching new markets, building high-performing teams, and supporting excellent clinical care delivery across diverse practice environments.
"I've worked closely with primary care providers for years and have tremendous respect for how they navigate a myriad of challenges, especially in areas where resources are tight and patient complexity is high,” said Shannon Jacobs. “What excites me about Counterpart Assistant is the opportunity to support these hard-working providers with valuable clinical data and AI-enabled technology that fits into their existing workflows and allows them to deliver high quality care to their patients.”
Counterpart Health, a subsidiary of Clover Health Investments, Corp., or Clover Health, is a leading AI-powered physician enablement platform transforming care delivery. Born out of Clover Health as Clover Assistant, Counterpart Health’s flagship software platform, Counterpart Assistant, provides clinically intuitive insights that help clinicians better manage chronic conditions and deliver high-quality care. Counterpart Health extends this powerful data-driven technology platform beyond Clover Health’s Medicare Advantage plan, bringing its benefits to a wider audience to improve patient outcomes and reduce healthcare costs nationwide. Several published studies demonstrate the technology’s impact on Diabetes, Chronic Kidney Disease, Congestive Heart Failure, and Chronic Obstructive Pulmonary Disease management, and Clinical Quality.
Investor Relations:
Ryan Schmidt
This email address is being protected from spambots. You need JavaScript enabled to view it.
Press Inquiries:
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.63 |
Daily Change: | 0.07 2.73 |
Daily Volume: | 6,677,323 |
Market Cap: | US$1.100B |
September 25, 2025 September 16, 2025 September 09, 2025 August 05, 2025 July 29, 2025 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load